Please join SFOG for an exclusive webinar with Innoblative.
Innoblative is an electrosurgical medical device company spun out from Northwestern University developing advanced radiofrequency ablation (“RFA”) technology for cancer therapy and beyond. Innoblative has 41 issued global patents, regulatory clearance (FDA 510k & CE Mark) on its SIRA™ device, and is preparing to launch commercially.
In solid cancers like early stage breast cancer, surgical resection of the tumor is standard of care. About 1-in-5 of these patients require both a second surgery to remove residual cancer left at the margin of the resected tissue (“positive margin”). Furthermore, most of these patients undergo an expensive and burdensome course of radiation therapy to treat residual cancer cells near the margin. Innoblative’s patented SIRA™ (Saline-coupled Intra-operative Radio-frequency Ablation) technology delivers RF energy to thermally ablate (kill) residual cancer left behind to reduce the need for re-operation surgeries and radiation therapy.